APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Jun 2017
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban
- Indications Embolism; Stroke
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 02 Jun 2017 Planned End Date changed from 1 Dec 2016 to 15 Nov 2017.
- 02 Jun 2017 Planned primary completion date changed from 1 Dec 2016 to 15 Nov 2017.
- 22 Mar 2016 According to ClinicalTrials.gov record, the patients no. has changed from 1800 to 18000.